By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The increasing efficiency of manufacturing companies in Tunisia is considered a key factor augmenting the growth of the pharmaceutical market in this region.
The rising prevalence of various illnesses in the gastronomy sector will also boost the market in the forecast period. Also, the rising popularity of product formulations mainly tablets and capsules is also projected to aid in favor of this market in the future.
On the contrary, factors such as the lack of standardization and regulatory policies may restrict the growth of this market in the coming years.
Nevertheless, Increasing number of pharmaceutical export activities from Tunisia to other non-African nations such as Libya, Mauritania, Algeria, and others is likely to create lucrative growth opportunities for this market in the forecast period.
With the rapidly developed private health care sector investments, Tunisia is leading the race to be the regional medical center. To enter the region, manufacturers require to obtain the Authorization for Market Commercialization (AMC) from the Directorate of Pharmacy and Pharmaceuticals (DPM) of the Republic of Tunisia.
The Pharmacy Centre, a government entity, controls all pharmaceutical imports and applies the “correlation” system under which, upon request from a Tunisian pharmaceutical manufacturer, the import of a foreign drug similar to the one produced locally could be banned.
In 2022, Tunisia’s economy continued to be heavily impacted by the effects of Russia’s further invasion of Ukraine. Despite a slow recovery from the COVID-19 pandemic, Tunisia’s GDP grew by only 2.4 percent in 2022 after 3.1 percent growth in 2021, and a record contraction of 8.8 percent in 2020.
The country still faces high unemployment, high inflation, and rising levels of public debt, in addition to shortages of food products, medicines, and energy commodities due to the ongoing invasion of Ukraine.
The registration of pharmaceutical drugs in Tunisia requires that the product is both registered and marketed in the country of origin. In 2005, Tunisia removed its restriction on pharmaceutical imports where there are similar generic products manufactured locally.
The pharmaceutical manufacturing industry in Tunisia is well-established, with numerous local businesses producing a variety of pharmaceutical goods, including generic medications, medical equipment, and vaccines.
The pharmaceutical industry value chain encompasses research & development activities, manufacturing inputs for the pharmaceutical industry and distribution channels.
The nation’s ability to produce certain important medicines locally has helped it become self-sufficient in certain products.Access to necessary medications for the public is a top priority for Tunisia.
Price limits, reimbursements for necessary medications, and the establishment of a national health insurance programme are just a few of the programmes that have been put in place to ensure affordability and accessibility.
In Tunisia, where the population is served by a network of pharmacies and medical facilities, the distribution of pharmaceutical items is well-organized.
The government is supporting the development of new drugs and technologies in the pharmaceutical sector and also to ensure the quality and safety of pharmaceuticals by combating counterfeit drugs.
The government is investing in training and education programs to create a skilled workforce for the pharmaceutical industry.
Tunisia relies heavily on imported medicines, making the market vulnerable to external factors like price fluctuations and supply chain disruptions.
Local companies may face difficulties securing financing for expansion and innovation initiatives.Established multinational pharmaceutical companies may pose significant competition to local players.
Political turmoil and economic uncertainty create an unpredictable environment, hindering investment and long-term planning for market players. Fluctuations in currency exchange rates can affect the cost of imported drugs and impact affordability. Public sector budget constraints limit government resources available to support the pharmaceutical sector.
Tunisia imports around 50% of its pharmaceuticals, leaving the market vulnerable to external factors like supply chain disruptions and price fluctuations in exporting countries. This dependence can also limit local production capacity and innovation potential.
The Tunisia pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The Tunisian government announced a new initiative to promote the development of the biopharmaceutical industry. This initiative includes funding for research and development, as well as tax breaks for companies investing in the sector.
Tunisia joined the Africa Medicines Regulatory Harmonization Initiative (AMRH). This initiative aims to harmonize pharmaceutical regulations across Africa, which would facilitate the free movement of medicines and vaccines within the continent.
The Tunisian government announced a new five-year plan for the pharmaceutical sector, aiming to increase local production by 50% and reduce dependence on imported drugs.
A new online platform for purchasing pharmaceuticals was launched in Tunisia. This platform allows users to compare prices, order medications, and have them delivered to their homes. The launch of this platform could increase access to pharmaceuticals for Tunisians, particularly those who live in rural areas or who have difficulty accessing traditional pharmacies. It could also promote competition in the pharmaceutical sector and lead to lower prices for consumers.
Pfizer announced its decision to close its manufacturing plant in Tunisia by the end of 2024. This decision comes as part of Pfizer’s global restructuring plan to streamline operations and reduce costs. This closure will result in the loss of approximately 200 jobs and could have a negative impact on the Tunisian pharmaceutical industry. Pfizer was one of the largest pharmaceutical companies operating in Tunisia, and its departure could discourage other foreign investors from entering the market.
Adwya introduces Revostat, a new generic version of the popular cholesterol-lowering medication atorvastatin.This medication is used to reduce the cholesterol in patients with obesity problems. It is a HMG-CoA reductase inhibitor (statin). It slows the production of cholesterol in the body.
Sanofi launches Dupixent for the treatment of moderate-to-severe atopic dermatitis, offering a new treatment option for this chronic inflammatory skin condition. Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trial.
Sanofi launches Toujeo and SoloStar, a new pre-filled pen for long-acting insulin (glargine) used to treat diabetes.It deliver breakthrough medicines for the management of diabetes with the launch of its new product. The next generation basal insulin. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.
